Meeting
2019 ASCO Annual Meeting
Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E/GEJ) cancer.
Authors
Nataliya Volodymyrivna Uboha
University of Wisconsin, Carbone Cancer Center, Madison, WI
Nataliya Volodymyrivna Uboha , James D. Maloney , Daniel McCarthy , Dustin A. Deming , Noelle K. LoConte , Kristina Matkowskyj , Jens C. Eickhoff , Philip Emmerich , Malcolm M. DeCamp , Sam Joseph Lubner , Anita Ahmed Turk , Michael Frederick Bassetti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03490292
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4041)
DOI
10.1200/JCO.2019.37.15_suppl.4041
Abstract #
4041
Poster Bd #
146
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study.
First Author: Richard Francis Dunne
Poster
2020 Gastrointestinal Cancers Symposium
Retrospective comparison of neoadjuvant chemoradiation (nCRT) +/- surgery using the CROSS trial regimen and definitive chemoradiation (dCRT) with carboplatin (C) and paclitaxel (P) in esophageal (EC), and gastroesophageal junction cancer (GEJC) in Canada.
First Author: Sidra Khalid
First Author: Igor Tsaur
Poster
2024 ASCO Annual Meeting
Neoadjuvant immuno-chemo-radiotherapy in operable esophageal and gastroesophageal junction adenocarcinoma with carboplatin, paclitaxel plus radiotherapy and avelumab (anti-PDL1 antibody): Neo-CREATE trial.
First Author: Amitesh Chandra Roy